优化USPSTF指南非依从女性的癌症筛查建模策略
研究发现,对不符合肺癌筛查条件者每年1次精心选择的筛查、符合条件者每年2次筛查,可保持至少94%的最大获益;省略肺癌筛查则获益≤25%。
要点
- 不符合肺癌筛查条件女性每年1次精选筛查可保持≥94%最大获益
- 符合肺癌筛查条件女性每年2次筛查可保持≥94%最大获益,但肺癌筛查不可省略
- 依从性提高1%-2%可使每年2次筛查方案达到2018年依从率下USPSTF推荐的同等获益
核心结论
- 对USPSTF癌症筛查指南非依从的女性,可降低筛查强度而总体获益仅轻微减少。
研究设计与样本
- 研究于2017年1月31日至2020年7月20日进行,模拟45种筛查策略,组合乳腺、宫颈、结直肠和/或肺癌筛查,限制为每年1、2、3或4次筛查或每5年一次所有合格筛查。
主要发现
- 对不符合肺癌筛查条件女性,每年1次精心选择的筛查可保持≥94%的最大获益。
- 对符合肺癌筛查条件女性,每年2次筛查可保持≥94%的最大获益;省略肺癌筛查的策略获益≤25%。
- 排名最高的每年2次筛查策略为年度肺癌筛查联合粪便免疫化学检测与乳腺X线摄影交替(当宫颈癌筛查到期时跳过乳腺X线摄影),达最大获益的97%。
- 在符合肺癌筛查条件且每年2次筛查的女性人群中,依从性提高1%-2%(取决于筛查检测)可使获益达到2018年依从率下USPSTF推荐的同等水平。
关键数值与推荐
- 不符合肺癌筛查条件女性每年1次筛查保持≥94%最大获益。
- 符合肺癌筛查条件女性每年2次筛查保持≥94%最大获益。
- 省略肺癌筛查的策略获益≤25%最大获益。
- 最优每年2次策略(年度肺癌筛查联合粪便免疫化学检测与乳腺X线摄影交替)达97%最大获益。
- 依从性提高1%-2%可使每年2次筛查方案获益等同于2018年依从率下USPSTF推荐。
临床怎么用
- 对无法完成所有USPSTF推荐筛查的女性,可考虑每年1次(不符合肺癌筛查条件)或2次(符合条件)的精选筛查方案以维持大部分获益。
- 在符合肺癌筛查条件女性中,应优先确保肺癌筛查不被省略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In 2018, only half of US women obtained all evidence-based cancer screenings. This proportion may have declined during the COVID-19 pandemic because of social distancing, high-risk factors, and fear. OBJECTIVE: To evaluate optimal screening strategies in women who obtain some, but not all, US Preventive Services Task Force (USPSTF)-recommended cancer screenings. DESIGN, SETTING, AND PARTICIPANTS: This modeling study was conducted from January 31, 2017, to July 20, 2020, and used 4 validated mathematical models from the National Cancer Institute's Cancer Intervention and Surveillance Modeling Network using data from 20 million simulated women born in 1965 in the US. INTERVENTIONS: Forty-five screening strategies were modeled that combined breast, cervical, colorectal, and/or lung cancer (LC) screenings; restricted to 1, 2, 3 or 4 screenings per year; or all eligible screenings once every 5 years. MAIN OUTCOMES AND MEASURES: Modeled life-years gained from restricted cancer screenings as a fraction of those attainable from full compliance with USPSTF recommendations (maximum benefits). Results were stratified by LC screening eligibility (LC-eligible/ineligible). We repeated the analysis with 2018 adherence rates, evaluating the increase in adherence required for restricted screenings to have the same population benefit as USPSTF recommendations. RESULTS: This modeling study of 20 million simulated US women found that it was possible to reduce screening intensity to 1 carefully chosen test per year in women who were ineligible for LC screening and 2 tests per year in eligible women while maintaining 94% or more of the maximum benefits. Highly ranked strategies screened for various cancers, but less often than recommended by the USPSTF. For example, among LC-ineligible women who obtained just 1 screening per year, the optimal strategy frequently delayed breast and cervical cancer screenings by 1 year and skipped 3 mammograms entirely. Among LC-eligible women, LC screening was essential; strategies omitting it provided 25% or less of the maximum benefits. The top-ranked strategy restricted to 2 screenings per year was annual LC screening and alternating fecal immunochemical test with mammography (skipping mammograms when due for cervical cancer screening, 97% of maximum benefits). If adherence in a population of LC-eligible women obtaining 2 screenings per year were to increase by 1% to 2% (depending on the screening test), this model suggests that it would achieve the same benefit as USPSTF recommendations at 2018 adherence rates. CONCLUSIONS AND RELEVANCE: This modeling study of 45 cancer screening strategies suggests that women who are noncompliant with cancer screening guidelines may be able to reduce USPSTF-recommended screening intensity with minimal reduction in overall benefits.
引用
- Taksler GB, Peterse EFP, Willems I, et al. Modeling Strategies to Optimize Cancer Screening in USPSTF Guideline-Noncompliant Women. JAMA Oncol. 2021. PMID: 33914025. doi:10.1001/jamaoncol.2021.0952
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。